S&P 500   5,081.22 (+0.23%)
DOW   38,891.64 (-0.15%)
QQQ   438.20 (+0.67%)
AAPL   180.15 (-0.70%)
MSFT   409.81 (+0.51%)
META   489.23 (+1.08%)
GOOGL   137.15 (+0.56%)
AMZN   175.03 (+1.08%)
TSLA   200.37 (-0.83%)
NVDA   793.23 (+2.14%)
NIO   5.66 (+4.24%)
AMD   191.06 (+8.22%)
BABA   74.03 (-0.75%)
T   16.99 (+0.18%)
F   12.41 (+0.89%)
MU   89.91 (+0.22%)
CGC   3.28 (-2.38%)
GE   156.03 (+0.27%)
DIS   111.33 (+0.48%)
AMC   4.30 (-13.83%)
PFE   26.78 (-0.96%)
PYPL   60.24 (-0.02%)
XOM   104.48 (+0.15%)
S&P 500   5,081.22 (+0.23%)
DOW   38,891.64 (-0.15%)
QQQ   438.20 (+0.67%)
AAPL   180.15 (-0.70%)
MSFT   409.81 (+0.51%)
META   489.23 (+1.08%)
GOOGL   137.15 (+0.56%)
AMZN   175.03 (+1.08%)
TSLA   200.37 (-0.83%)
NVDA   793.23 (+2.14%)
NIO   5.66 (+4.24%)
AMD   191.06 (+8.22%)
BABA   74.03 (-0.75%)
T   16.99 (+0.18%)
F   12.41 (+0.89%)
MU   89.91 (+0.22%)
CGC   3.28 (-2.38%)
GE   156.03 (+0.27%)
DIS   111.33 (+0.48%)
AMC   4.30 (-13.83%)
PFE   26.78 (-0.96%)
PYPL   60.24 (-0.02%)
XOM   104.48 (+0.15%)
S&P 500   5,081.22 (+0.23%)
DOW   38,891.64 (-0.15%)
QQQ   438.20 (+0.67%)
AAPL   180.15 (-0.70%)
MSFT   409.81 (+0.51%)
META   489.23 (+1.08%)
GOOGL   137.15 (+0.56%)
AMZN   175.03 (+1.08%)
TSLA   200.37 (-0.83%)
NVDA   793.23 (+2.14%)
NIO   5.66 (+4.24%)
AMD   191.06 (+8.22%)
BABA   74.03 (-0.75%)
T   16.99 (+0.18%)
F   12.41 (+0.89%)
MU   89.91 (+0.22%)
CGC   3.28 (-2.38%)
GE   156.03 (+0.27%)
DIS   111.33 (+0.48%)
AMC   4.30 (-13.83%)
PFE   26.78 (-0.96%)
PYPL   60.24 (-0.02%)
XOM   104.48 (+0.15%)
S&P 500   5,081.22 (+0.23%)
DOW   38,891.64 (-0.15%)
QQQ   438.20 (+0.67%)
AAPL   180.15 (-0.70%)
MSFT   409.81 (+0.51%)
META   489.23 (+1.08%)
GOOGL   137.15 (+0.56%)
AMZN   175.03 (+1.08%)
TSLA   200.37 (-0.83%)
NVDA   793.23 (+2.14%)
NIO   5.66 (+4.24%)
AMD   191.06 (+8.22%)
BABA   74.03 (-0.75%)
T   16.99 (+0.18%)
F   12.41 (+0.89%)
MU   89.91 (+0.22%)
CGC   3.28 (-2.38%)
GE   156.03 (+0.27%)
DIS   111.33 (+0.48%)
AMC   4.30 (-13.83%)
PFE   26.78 (-0.96%)
PYPL   60.24 (-0.02%)
XOM   104.48 (+0.15%)
NASDAQ:CLSN

Imunon (CLSN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$1.95
$2.63
52-Week Range
N/A
Volume
711 shs
Average Volume
150,471 shs
Market Capitalization
$13.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CLSN stock logo

About Imunon Stock (NASDAQ:CLSN)

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.


CLSN Stock News Headlines

CLSN.L Regulatory News
Rare Earth Elements: The Workhorse of The Tech Revolution
They're the most underrated yet crucial elements of technology. From renewable energy to military defense, Rare Earths are essential pieces of modern technology. Global superpowers and savvy investors are quickly learning just how valuable they truly are.
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
Recap: Celsion Q2 Earnings - Benzinga
See More Headlines
Receive CLSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/15/2022
Today
2/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CLSN
Employees
27
Year Founded
1982

Profitability

Net Income
$-20,770,000.00
Net Margins
-5,229.80%
Pretax Margin
-5,506.60%

Debt

Sales & Book Value

Annual Sales
$500,000.00
Book Value
$9.66 per share

Miscellaneous

Free Float
6,768,000
Market Cap
$13.91 million
Optionable
Optionable
Beta
2.27

Social Links

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Michael H. Tardugno (Age 71)
    Exec. Chairman
    Comp: $1.01M
  • Mr. Jeffrey W. Church CPA (Age 65)
    CPA, CFO, Exec. VP & Corp. Sec.
    Comp: $528.54k
  • Dr. Khursheed Anwer M.B.A. (Age 62)
    Ph.D., Exec. VP & Chief Scientific Officer
    Comp: $511.92k
  • Dr. Nicholas Borys (Age 63)
    Exec. VP & Chief Medical Officer
    Comp: $586.54k
  • Dr. Corinne Le Goff M.B.A.
    Pharm.D., CEO, Pres & Director
  • Mr. Timothy J. Tumminello (Age 64)
    Chief Accounting Officer & Controller
  • Ms. Marianne M. Lambertson
    VP of Communications & Investor Relations














CLSN Stock Analysis - Frequently Asked Questions

How were Imunon's earnings last quarter?

Imunon, Inc. (NASDAQ:CLSN) released its earnings results on Monday, August, 15th. The biotechnology company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.25. Imunon had a negative net margin of 5,229.80% and a negative trailing twelve-month return on equity of 50.18%. During the same quarter last year, the firm earned ($0.90) earnings per share.

When did Imunon's stock split?

Shares of Imunon reverse split on the morning of Tuesday, March 1st 2022. The 1-15 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Imunon own?
This page (NASDAQ:CLSN) was last updated on 2/29/2024 by MarketBeat.com Staff